Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Tempest Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +3 vs. Q4 2025
- Shares held
- 786.9K
- +163.0K (+26.1%) vs. Q4 2025
- Total value
- $1.29M
- −$500.0K (−27.9%) vs. Q4 2025
- New holders
- 5
- 3 more added
- Sold out
- 2
- 3 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TPST on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $1.44M |
| Q1 2026 | 22 | $1.29M |
| Q4 2025 | 21 | $2.26M |
| Q3 2025 | 17 | $6.02M |
| Q2 2025 | 18 | $6.42M |
| Q1 2025 | 24 | $4.42M |
| Q4 2024 | 35 | $5.66M |
| Q3 2024 | 28 | $3.94M |
| Q2 2024 | 24 | $4.70M |
| Q1 2024 | 30 | $7.58M |
| Q4 2023 | 32 | $9.88M |
| Q3 2023 | 24 | $1.05M |
| Q2 2023 | 22 | $4.86M |
| Q1 2023 | 17 | $8.72M |
| Q4 2022 | 13 | $3.54M |
| Q3 2022 | 16 | $5.36M |
| Q2 2022 | 16 | $6.67M |
| Q1 2022 | 15 | $7.12M |
| Q4 2021 | 19 | $12.4M |
| Q3 2021 | 22 | $31.8M |
| Q2 2021 | 24 | $20.5M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Tempest Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Versant Venture Management, LLC | 269,772 | $442.4K | 0.31% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 233,888 | $383.6K | 0.00% | +233,888 | New |
| Geode Capital Management, LLC | 86,990 | $142.7K | 0.00% | +42,878+97.2% | Added |
| Vanguard Fiduciary Trust Co | 68,908 | $113.0K | 0.00% | +68,908 | New |
| BlackRock, Inc. | 39,068 | $64.1K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 33,225 | $54.5K | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 17,856 | $29.3K | 0.51% | −160,736−90.0% | Reduced |
| Northern Trust Corp | 14,053 | $23.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 11,444 | $18.8K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,533 | $7.43K | 0.00% | −13,009−74.2% | Reduced |
| Tower Research Capital LLC (TRC) | 2,790 | $4.58K | 0.00% | +1,465+110.6% | Added |
| Morgan Stanley | 2,058 | $3.38K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,529 | $2.50K | 0.00% | −84−5.2% | Reduced |
| Federation des caisses Desjardins du Quebec | 292 | $479 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 239 | $413 | 0.00% | 00.0% | Unchanged |
| Vanguard Global Advisers, LLC | 168 | $276 | 0.00% | +168 | New |
| SBI Securities Co., Ltd. | 56 | $92 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 18 | $30 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 8 | $13 | 0.00% | +8 | New |
| JPMorgan Chase & Co | 5 | $8 | 0.00% | +5 | New |
| BNP Paribas Arbitrage, SA | 3 | $5 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 27 | $0 | 0.00% | +19+237.5% | Added |
| DRW Securities, LLC | 0 | $0 | 0.00% | −10,447−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |